open access - NEJM: Niraparib Maintenance Therapy in Platinum- Sensitive, Recurrent Ovarian Cancer Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, October 10, 2016

open access - NEJM: Niraparib Maintenance Therapy in Platinum- Sensitive, Recurrent Ovarian Cancer



pdf

CONCLUSIONSAmong patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence
of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded
by Tesaro
; ClinicalTrials.gov number, NCT01847274.)

0 comments :

Post a Comment

Your comments?